Using bispecific antibodies to help patients after bone marrow transplants
Official title: Bispecific Antibody Maintenance Therapy after Allogeneic Bone Marrow Transplant
Funded at Johns Hopkins University · NIH-10889029 · Data updated 2026-11-12
This study is looking at a new treatment using special antibodies to help patients who have had a bone marrow transplant for acute leukemias, like acute lymphoblastic leukemia and acute myeloid leukemia, to boost their immune system against any leftover cancer cells and hopefully keep them healthy for longer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 17, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $237,049 |
| NIH project number | 5K08CA276987-02 |
| Project ID | NIH-10889029 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have received an allogeneic bone marrow transplant for acute lymphoblastic leukemia or acute myeloid leukemia.
✕Less likely to help
Patients who have not undergone an allogeneic bone marrow transplant or those with other types of leukemia may not benefit from this research.
What this research studies
This research investigates the use of bispecific antibodies as a maintenance therapy for patients who have undergone allogeneic bone marrow transplants for acute leukemias. The approach aims to enhance the immune response against residual cancer cells while minimizing the risk of complications associated with traditional therapies. By focusing on patients with acute lymphoblastic leukemia and acute myeloid leukemia, the study seeks to improve long-term outcomes and reduce the chances of disease relapse. The research is being conducted at Johns Hopkins University, where a team of experts in oncology and hematologic malignancies is involved.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients recovering from acute leukemia after bone marrow transplantation.
How similar studies have gone: Previous research has shown promising results with bispecific antibodies in similar contexts, indicating potential for success in this novel application.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Webster, Jonathan Allen — Johns Hopkins University
- Study coordinator: Webster, Jonathan Allen
Related research
Other NIH-funded projects on the same topics.
-
Targeting early oral GVHD to improve mouth health after stem cell transplant
A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.
-
Innate and Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
A liver transplant-focused project investigates how the body’s early and later immune responses affect transplant failure or success after reperfusion.
-
Exercise-based frailty program for people awaiting lung transplants
A tailored exercise and lifestyle program is being tested to reduce frailty and improve outcomes for people waiting for a lung transplant.
-
Diabetes and Donor Tissue in Corneal Transplants
This grant studies whether corneas from donors with diabetes affect the success of Descemet membrane endothelial keratoplasty (DMEK) and what factors predict better or worse outcomes.
-
Microbial clues to diagnose and predict infections in kidney transplant patients
A patient-focused project will look for microbial biomarkers in stool, blood, and urine to help doctors predict and diagnose infections in people who have had a kidney transplant.
-
Medicare Advantage and Transplant Access for Rural and Vulnerable Communities
Aimed at understanding how Medicare Advantage affects early steps to kidney transplant for adults in rural or socioeconomically challenged groups.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.